Free ₹200 worth HealthCash on app
Use HealthCash to order medicines, health products & much more
Get App

Tosiban 37.5 Injection

Manufactured byZUVENTUS HEALTHCARE LTD
ContainsAtosiban
CURRENTLY UNAVAILABLE

Confused about any medicine? Just ask Practo AIFREE

50000+ health queries resolved in last month

Chat with Practo AI on Whatsapp

Not finding what you need? Ask Practo AI

FREE

Chat with Practo AI on Whatsapp

Description

Tosiban 37.5 Injection is a medicine used to delay the premature birth of a baby in pregnancies between 24-33 weeks of gestation. However, this medicine can only be used in certain specific clinical conditions.

Substitutes

List of substitutes for Tosiban 37.5 Injection

Side effects

Major & minor side effects for Tosiban 37.5 Injection

Nausea and Vomiting

Headache

Hot flushes

Fast heartbeat

Low blood pressure

Injection site redness, bruising, or sores

Increased blood sugar levels

Fever

Difficulty in falling asleep

Itching and skin rash

Vaginal bleeding post birth

Shortness of breath

Uses of Tosiban 37.5 Injection

What is it prescribed for?

Delay of imminent pre-term birth

This medicine is used to delay an imminent pre-term birth in women whose pregnancy is between 24-33 weeks of gestation. Some clinical conditions to be met for the administration of this medicine are as follows: − regular uterine contractions of at least 30 seconds' duration at a rate of ≥ 4 per 30 minutes. − cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50%. − a gestational age from 24 until 33 completed weeks. − a normal fetal heart rate.
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?

    The effect of this medicine can be observed within 10 minutes of administration of the dose.
  • How long do the effects of this medicine last?

    Since this medicine is administered until the uterine contractions stop, the duration of action of this medicine cannot be clinically determined.
  • Is it safe to consume alcohol while taking this medicine?

    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?

    No habit-forming tendencies were reported.
  • Can this medicine be taken during pregnancy?

    This medicine is recommended for use in pregnant women only when the specified conditions are met. Your doctor will determine the course of treatment with this medicine after assessing the clinical condition.
  • Can this medicine be taken while breast-feeding?

    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. Your doctor will determine the course of treatment with this medicine after assessing your clinical condition. Your doctor may advise you to discontinue breastfeeding during treatment with this medicine.

Allergy

This medicine is not recommended for use in patients with a known allergy to atosiban or any other inactive ingredients present in the formulation.

Gestational age

This medicine is not recommended for use in pregnant women with a gestational age lesser than 24 weeks or greater than 33 weeks due to the increased risk of worsening of the patient’s condition.

Premature rupture of membranes

This medicine is not recommended for use if there is a premature rupture of the membranes or breakage of the amniotic sac and the pregnancy is more than 30 weeks old.

Antepartum uterine hemorrhage

This medicine is not recommended for use in case of serious vaginal bleeding requiring immediate delivery during pregnancy due to the increased risk of worsening of the patient’s condition.

Eclampsia

This medicine is not recommended for use in pregnant women suffering from eclampsia, a potentially dangerous complication characterized by high blood pressure, swelling of the hands and feet, and the presence of protein in the urine, since it may worsen the patient's condition.

Intrauterine fetal death

This medicine is not recommended for use in case of a stillbirth or intrauterine fetal death due to any pregnancy-related complications.

Intrauterine infection

This medicine is not recommended for use in pregnancies where infection of the uterus is suspected or confirmed due to the increased risk of worsening of the patient’s condition.

Placenta previa

This medicine is not recommended for use in pregnancies complicated by placenta previa, a condition where the placenta covers the opening of the cervix, since it may worsen the patient's condition.

Placental abruption

This medicine is not recommended for use in pregnancies complicated by placental abruption, a serious condition where the placenta detaches from the uterus, since it may worsen the patient's condition.

Other serious pregnancy related complications

This medicine is not recommended for use in patients suffering from pregnancy-related complications where continuation of pregnancy is considered hazardous.

Warnings for special population

Pregnancy

This medicine is recommended for use in pregnant women only when the specified conditions are met. Your doctor will determine the course of treatment with this medicine after assessing the clinical condition.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. Your doctor will determine the course of treatment with this medicine after assessing your clinical condition. Your doctor may advise you to discontinue breastfeeding during treatment with this medicine.

General warnings

Other medicines

Tosiban 37.5 Injection may interact with many other medicines and may cause severe adverse effects. Certain medicines taken for treating high blood pressure levels may cause unwanted complications when used along with Tosiban 37.5 Injection. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.

Use in children

This medicine is not recommended for use in pregnant women aged less than 18 years of age since the safety and efficacy of use are not clinically established in such patients.

Premature rupture of membrane

This medicine should be used with extreme caution if rupture of the membranes is suspected. The benefits of delaying delivery should be balanced against the risk of chorioamnionitis before beginning treatment with this medicine.

Re-treatment with this medicine

This medicine can be used for 3 treatment cycles in certain special circumstances. However, in cases of fetal growth retardation, the decision to continue or re-initiate treatment with this medicine depends on the fetal maturity levels.

Monitoring of uterine contractions

It is recommended to frequently monitor the uterine contractions while administering this medicine.

Monitoring of fetal heart rate

It is recommended to frequently monitor the fetal heart rate while administering this medicine.

Gestational age of 24-27 weeks

This medicine should be used with caution in pregnancies that are less than 27 weeks old and more than 24 weeks old. Close monitoring of the clinical condition is necessary for these patients.

Blood loss after delivery

Use of this medicine may cause vaginal bleeding after delivery and hence close clinical monitoring is advised during and post administration of this medicine.

Multiple pregnancy

This medicine should be used with extreme caution if the patient has more than one baby in the womb (twins, triplets, or more).

Missed Dose

Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting for a continuous period of not more than 48 hours, the likelihood of a missed dose is very low.

Overdose

Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.

Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Interaction with Medicine

Salmeterol

Salbutamol

Disease interactions

Liver Disease

This medicine should be used with caution in patients with liver diseases due to the increased risk of severe adverse effects. Regular monitoring of the liver function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Food interactions

Information not available.

Lab interactions

Information not available.
Treatment with this medicine should be initiated and maintained by a doctor who is experienced in dealing with pre-term labor, preferably in a healthcare facility. Monitoring of uterine contractions and fetal heart rate may be needed while this medicine is administered. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines and your medical history to the doctor before receiving treatment with this medicine.

Miscelleneous

Usage does not depend on food timings

To be taken as instructed by doctor

Does not cause sleepiness

How it works

This medicine works by blocking the effect of a certain hormone, thereby making the contractions of the womb weaker and less frequent.

Legal Status

Approved

Unknown

Approved

Unknown

Classification

Category

Tocolytic agents

Schedule

Schedule G

[Internet]. Ema.europa.eu. 2018 [cited 28 August 2018]. Available from:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000253/WC500040495.pdf

[Internet]. Medicines.org.uk. 2018 [cited 28 August 2018]. Available from:

https://www.medicines.org.uk/emc/files/pil.3262.pdf

Atosiban - DrugBank [Internet]. Drugbank.ca. 2018 [cited 28 August 2018]. Available from:

https://www.drugbank.ca/drugs/DB09059

Reinheimer TM e. Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus mo... - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 2018 [cited 28 August 2018]. Available from:

https://www.ncbi.nlm.nih.gov/pubmed/15671092

Related Questions

Something doesn’t feel right?
Report an error

Information on this page was last updated on 2 Jan 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.